Global Leader in Oral Delivery of Therapeutic Proteins
We are a clinical stage company developing oral peptide and protein replacement therapies for significant unmet needs where an oral tablet holds the potential to transform the standard of care.
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk.
Hypoparathyroidism is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or the parathyroid hormone produced lacks biologic activity.
We have a collaboration agreement with OPKO to leverage our N-Tab™ technology for the development of an oral GLP-2 for Short Bowel Syndrome and GLP-1/glucagon for obesity.
Entera leverages a disruptive and proprietary oral delivery technology platform (N-Tab™) that is designed to stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
Our pipeline includes five differentiated, first-in-class oral peptide programs expected to enter the clinic by 2025.